Arcutis Biotherapeutics (ARQT) Has Favorable Risk/Reward, Multiple Catalysts to Look Up to - Mizuho Securities
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear reiterated a Buy rating and $58.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
